beta

ACRS

Aclaris Therapeutics, Inc.

Acrs

Chart

Stats

Earnings

News

Splits

Dividends

Earnings

Actual EPS
Consensus EPS
Estimated EPS
Number of Estimates
EPS Surprise

Stats

Summary

Aclaris Therapeutics, Inc. operates as a dermatologist-led biopharmaceutical company, which engages in identifying, developing, and commercializing novel drugs to address the needs in medical and aesthetic dermatology and immunology. It operates through Dermatology Therapeutics and Contract Research segments. The Dermatology Therapeutics segment focuses in identifying, developing, and commercializing innovative and differentiated therapies to address significant unmet needs in medical and aesthetic dermatology. The Contract Research segment provides laboratory services under contract research arrangements to pharmaceutical and biotech companies. The company was founded by Neal S. Walker, Frank Ruffo, Kamil Ali-Jackson, Christopher V. Powala, and Stuart D. Shanler in July 2012 and is headquartered in Malvern, PA.

Market Cap: 77.8 Million

Primary Exchange: NASDAQ

Website: http://www.aclaristx.com

Shares Outstanding: 41.4 Million

Float: 32.6 Million

Dividend: (%)

Beta: 1.51364349101456

Sector: Health Technology

Industry: Pharmaceuticals: Other

Ethical Flags

Animal testing

Longest drawdown: 683 trading days

From: 2017-04-17 To: 2019-12-13

Lowest Point:

Teva hits 19-year low on continued pricing pressure

via: SeekingAlpha at 2019-06-12 06:49:59:000

Teva Pharmaceutical Industries ( TEVA -4.2% ) slumps on modestly higher volume. Shares are now exchanging hands at the lowest prices in 19 years. The stock continues to fight pricing headwinds, the continued erosion of Copaxone sales (down 56% in Q1) and its potential exposure from opioid … read more...

Teva hits 19-year low on continued pricing pressure

via: SeekingAlpha at 2019-06-12 06:49:59:000

Teva Pharmaceutical Industries ( TEVA -4.2% ) slumps on modestly higher volume. Shares are now exchanging hands at the lowest prices in 19 years. The stock continues to fight pricing headwinds, the continued erosion of Copaxone sales (down 56% in Q1) and its potential exposure from opioid … read more...

Ex-Date Payment Date Record Date Declared Date Amount Flag Dividend Type Qualified Indicated
Ex-Date Declared Date Record Date Payment Date Ratio To Factor For Factor
Data provided by IEX Cloud